Skip to main content

Advertisement

Log in

2007 highlights of advances in the pharmaceutical sciences: An American Association of Pharmaceutical Scientists (AAPS) perspective

  • Published:
The AAPS Journal Aims and scope Submit manuscript

An Erratum to this article was published on 01 September 2007

Abstract

The American Association of Pharmaceutical Scientists (AAPS) covers the full range of areas of expertise associated with the resolution of concerns pertaining to drugs and drug products. This editorial highlights the initiatives, issues, and challenges that are the forefront of the pharmaceutical sciences in 2007. It also provides an overview of how these difficult questions are being addressed through the programs and events associated with the AAPS 2007 Annual Meeting that will be held at the San Diego, California, Convention Center from November 11 to 15, 2007.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Society of Non-Invasive Imaging in Drug Development. Available at: http://www.snidd.org/. Accessed April 30, 2007.

  2. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs.Nat Rev Mol Cell Biol. 2007;8:23–36.

    Article  PubMed  CAS  Google Scholar 

  3. Pascual DM, Morales RD, Gil ED, Munoz LM, Lopez JE, Casanueva OL. Adjuvants: present regulatory challenges.Vaccine. 2006;24:S88-S89.

    Article  Google Scholar 

  4. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy.Nat Rev Cancer. 2007;7:95–106.

    Article  PubMed  CAS  Google Scholar 

  5. Marincola FM. Translational medicine: a two-way road.J Translational, Med. 2003;1:1–2.

    Article  Google Scholar 

  6. About the Clinical Pharmacology and Translational Research, (CPTR) Section Goals and Mission. Availablet at:http://www. aapspharmaceutica.com/inside/sections/cptr/about/goals.asp.Accessed May 11, 2007.

  7. Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten Phase II clinical trials of pemetrexed in cancer patients.Cancer Chemother Pharmacol. 2006;57:401–411.

    Article  PubMed  Google Scholar 

  8. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.Cancer Chemother Pharmacol. 2006;57:412–426.

    Article  PubMed  Google Scholar 

  9. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.Cancer Chemother Pharmacol. 2006;57:427–435.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marilyn N. Martinez.

Additional information

Published: June 22, 2007

(formerly Tyco Healthcare Mallinckrodt)

An erratum to this article is available at http://dx.doi.org/10.1208/aapsj0903038c.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martinez, M.N., Bonate, P., Chapman, R.L. et al. 2007 highlights of advances in the pharmaceutical sciences: An American Association of Pharmaceutical Scientists (AAPS) perspective. AAPS J 9, 24 (2007). https://doi.org/10.1208/aapsj0902024

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/aapsj0902024

Keywords

Navigation